- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04502602
Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer (iNNOVATE)
A Phase 1/1b Clinical Trial of Niraparib and Neratinib in Advanced Solid Tumors With an Expansion Cohort in Platinum-resistant Ovarian Cancer
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Massey Team Echo
- Email: ctoclinops@vcu.edu
Study Contact Backup
- Name: Massey SIIT Team
- Phone Number: 804-628-9238
- Email: masseysiit@vcu.edu
Study Locations
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Recruiting
- Virginia Commonwealth University
-
Contact:
- Massey Team Echo
- Email: ctoclinops@vcu.edu
-
Contact:
- Massey SIIT Team
- Phone Number: 804-628-9238
- Email: masseysiit@vcu.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Disease Characteristics
- Phase 1: Patients with advanced solid tumors, excluding primary CNS and prostate tumors, that have progressed during or after treatment with approved therapies or for which there is no standard effective therapy available or
- Phase 1b: Female patients with ovarian cancer who:
- Are platinum resistant (progressed within 6 months of finishing platinum therapy) and
- Have received at least 2 prior lines of therapy and
- Do not have a BRCA germline mutation
- Measurable or evaluable disease by RECIST 1.1
- Age ≥ 18 years
- ECOG performance status 0 or 1
Adequate bone marrow function as defined below:
- Absolute neutrophil count (ANC) ≥ 1,500/mm3
- Platelets ≥ 100,000/mm3 (untransfused)
- Hemoglobin ≥9 g/dL (untransfused)
Adequate renal function as defined below:
- Serum creatinine ≤ 1.5 x upper limit of normal (ULN) for the laboratory OR calculated
- Or actual creatinine clearance ≥ 30 mL/min (see Appendix 2 for the Cockcroft-Gault formula for calculating creatinine clearance)
Adequate hepatic function as defined below:
- Total bilirubin ≤ 1.5 x ULN for the laboratory OR direct bilirubin ≤ 1.0 x ULN
- Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x ULN (≤ 3x ULN when liver metastases are present)
- Patients receiving corticosteroids may continue as long as their dose is stable for least 4 weeks prior to initiating protocol therapy
- Patients must agree not to donate blood during the study or for 90 days after the last dose of study treatment
A woman of childbearing potential (WCBP) must have a documented negative serum pregnancy test within 7 days prior to initiating study treatment and agree to abstain from activities that could result in pregnancy from screening through 90 days after the last dose of study treatment. Non Childbearing potential is defined as follows (by other than medical reasons):
- ≥45 years of age and has not had menses for >1 year
- Patients who have been amenorrhoeic for <2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone (FSH) value in the postmenopausal range upon screening evaluation
- Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure, otherwise the patient must be willing to use 2 adequate barrier methods throughout the study, starting with the screening visit through 180 days after the last dose of study treatment. Information must be captured appropriately within the site's source documents. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient.
- Participant must agree to not breastfeed during the study or for 30 days after the last dose of study treatment.
- Male participant agrees to use an adequate method of contraception starting with the first dose of study treatment through 90 days after the last dose of study treatment. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient.
- Participant must agree to not donate sperm during the study or for 90 days after the last dose of study treatment
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Any investigational agent within 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is shorter, prior to initiating study treatment
- Simultaneous enrollment in any other interventional clinical trial
- Active, uncontrolled diarrhea leading to dehydration or electrolyte disturbances not controlled with oral repletion
- Serious (ie, grade ≥ 3) uncontrolled infection
- Major surgery ≤ 3 weeks prior to initiating study treatment and patient must have recovered from any surgical effects.
- Radiation encompassing >20% of the bone marrow within 2 weeks, or any radiation therapy within 1 week, prior to initiating study treatment.
- Transfusion of platelets or red blood cells ≤ 4 weeks prior to initiating study treatment
- Receipt of colony-stimulating factors (e.g., granulocyte colony-stimulating factor [GCSF], granulocyte macrophage colony- stimulating factor [GM-CSF], or recombinant erythropoietin) within 4 weeks prior to initiating study treatment
- Known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)
- Known brain or leptomeningeal metastasis
- Diagnosis, detection, or treatment of another type of invasive cancer ≤ 2 years prior to initiating study treatment
Active or clinically significant cardiac disease including any of the following;
- Unstable angina (eg, angina symptoms at rest) or onset of angina within 3 months prior to initiating study treatment
- Myocardial infarction diagnoses within 6 months prior to initiating study treatment
- New York Heart Association (NYHA) class III or IV congestive heart failure
- Uncontrolled hypertension
- Inability to swallow medication
- Known hypersensitivity to niraparib or neratinib components or excipients
- Known or suspected malabsorption condition or obstruction Note: Use of pancreatic enzyme supplements is allowed to control malabsorption
Inability to shift medications as follows:
- Antacids (eg, calcium carbonate): dose at least 3 hours after dosing with neratinib
- H2 receptor antagonists: dose must be taken at least 2 hours after or 10 hours before dosing with neratinib
Planned ongoing treatment with other drugs thought to potentially have adverse interactions with either of the medications included in the study treatment:
- Proton pump inhibitors (PPIs). Must discontinue use 10 days prior to initiating study therapy.
- High-risk P-glycoprotein (P-gp) substrates (eg, digoxin, dabigatran).
- Strong or moderate CYP3A4 inhibitors and/or Strong or moderate CYP3A4 inducers. Examples of clinical inhibitors and clinical inducers for P450-mediated metabolism and classification of strong, moderate, and weak interactions are available through the FDA website: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm
- If such medications have been used, patients must have discontinued these agents ≥ 2 weeks prior to initiating study treatment.
- Pregnancy or breastfeeding
- Medical, psychological, or social condition that, in the opinion of the investigator, may increase the patient's risk or limit the patient's adherence with study requirements
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose Level -1
Neratinib 160 mg and Niraparib 100 mg by mouth once daily for 28 day cycles.
|
Escalating doses to determine recommended phase 2 dose (RP2D)
Escalating doses to determine recommended phase 2 dose (RP2D)
|
Experimental: Dose Level 1
Neratinib 160 mg and Niraparib 200 mg by mouth once daily for 28 day cycles.
|
Escalating doses to determine recommended phase 2 dose (RP2D)
Escalating doses to determine recommended phase 2 dose (RP2D)
|
Experimental: Dose Level 2
Neratinib 200 mg and Niraparib 200 mg by mouth once daily for 28 day cycles.
|
Escalating doses to determine recommended phase 2 dose (RP2D)
Determined RP2D dose
|
Experimental: Dose Level 3
Neratinib 240 mg and Niraparib 200 mg by mouth once daily for 28 day cycles.
|
Escalating doses to determine recommended phase 2 dose (RP2D)
Escalating doses to determine recommended phase 2 dose (RP2D)
|
Experimental: Dose Level 4
Neratinib 240 mg and Niraparib 300 mg by mouth once daily for 28 day cycles.
|
Escalating doses to determine recommended phase 2 dose (RP2D)
Phase 1: Escalating doses to determine recommended phase 2 dose (RP2D)
|
Experimental: Phase 1b: Platinum Resistant Expansion Cohort
This portion of the study provides for cohort expansion to observe for 4 month or greater progression-free survival in patients with platinum resistant ovarian cancer treated at the recommended phase 2 dose (RP2D) determined in Phase I.
|
Phase 1b: Determined dose
Phase 1b: Determined dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1: To determine the Recommended phase 2 dose (RP2D) of niraparib and neratinib in patients with advanced solid tumors
Time Frame: 4 Months
|
The RP2D will be identified during the phase 1 dose escalation portion of the study using a modified 3+3 design and evaluated in a phase 1b dose expansion cohort of up to 12 patients with platinum-resistant ovarian cancer.
|
4 Months
|
Phase 1b: To evaluate clinical benefit (≥4-month progression-free survival [PFS]) of niraparib and neratinib in patients with platinum-resistant ovarian cancer.
Time Frame: 4 months
|
Phase 1b: To evaluate clinical benefit (≥4-month progression-free survival [PFS]) of niraparib and neratinib given at the RP2D to in patients with platinum-resistant ovarian cancer.
To evaluate the clinical benefit, (defined as ≥4-month progression free survival (PFS), using Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria in patients with platinum-resistant ovarian cancer.
|
4 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess the frequency of adverse events (AEs)
Time Frame: 5 months
|
To assess adverse events (AEs) characterized and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE V 5.0) to determine safety and toxicity of the combination of neratinib and niraparib
|
5 months
|
Preliminary efficacy (objective response rate [ORR]) of niraparib and neratinib in patients with advanced solid tumors.
Time Frame: 5 years
|
To evaluate the objective response rate (ORR): The percentage of patients with objective response either partial response (PR) or complete response(CR), by analysis using RECIST 1.1 criteria
|
5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Andrew Poklepovic, MD, Massey Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Poly(ADP-ribose) Polymerase Inhibitors
- Niraparib
Other Study ID Numbers
- MCC-18-14152
- NCI-2020-05315 (Other Identifier: NCI CTRP)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ovarian Cancer
-
Roswell Park Cancer InstituteCompletedFallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Stage IIA Ovarian Cancer | Stage IIB Ovarian Cancer | Stage IIC Ovarian Cancer | Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian Cancer | Stage IA Ovarian Cancer | Stage IB Ovarian Cancer | Stage IC... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedCancer Survivor | Stage IIIA Ovarian Epithelial Cancer | Stage IIIB Ovarian Epithelial Cancer | Stage IIIC Ovarian Epithelial Cancer | Stage IIA Ovarian Epithelial Cancer | Stage IIB Ovarian Epithelial Cancer | Stage IIC Ovarian Epithelial Cancer | Stage IA Ovarian Epithelial Cancer | Stage IB Ovarian... and other conditionsUnited States
-
Massachusetts General HospitalJohns Hopkins University; M.D. Anderson Cancer Center; National Cancer Institute... and other collaboratorsRecruitingOvarian Neoplasms | Fallopian Tube Neoplasms | Stage III Ovarian Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage IIIA1 Ovarian Cancer AJCC v8 | Stage IIIA2 Ovarian Cancer AJCC v8 | Stage IIIB Ovarian Cancer AJCC v8 | Stage IIIC Ovarian Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Malignant Ovarian Epithelial Tumor | Ovarian Carcinosarcoma | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditionsUnited States
-
Eve RodlerNot yet recruitingBreast Cancer | Ovarian Cancer | Breast Neoplasm | Breast Carcinoma | Breast Cancer Stage IV | Breast Cancer Stage I | Breast Cancer Stage II | Invasive Breast Cancer | Cancer, Breast | Breast Cancer Stage III | Ovary Cancer | Malignant Tumor of Breast | Ovarian Cancer Stage IIIC | Ovarian Cancer Stage IV | Ovarian Cancer... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)RecruitingStage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedStage IIA Fallopian Tube Cancer | Stage IIA Ovarian Cancer | Stage IIB Fallopian Tube Cancer | Stage IIB Ovarian Cancer | Stage IIC Fallopian Tube Cancer | Stage IIC Ovarian Cancer | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian... and other conditionsUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedCaregiver | Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Centre Leon BerardCancer Côte d'or registry; Cancer Calvados registryUnknownOvarian Epithelial CancerFrance
Clinical Trials on Neratinib 160 mg
-
Genencell Co. Ltd.Recruiting
-
RemeGen Co., Ltd.RecruitingPrimary Sjogren's SyndromeChina
-
Federation Francophone de Cancerologie DigestiveCompletedColorectal AdenocarcinomaFrance
-
Palobiofarma SLFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauTerminated
-
Yuhan CorporationActive, not recruitingNon-Small Cell Lung CancerHungary, Korea, Republic of, Australia, Taiwan, Serbia, Singapore, Thailand, Philippines, Turkey, Malaysia, Russian Federation, Greece, Ukraine
-
Ferring PharmaceuticalsCompletedProstate CancerUnited States, Netherlands, Hungary, Czech Republic, Germany, Mexico, Romania, Russian Federation, Ukraine, Canada, Puerto Rico, United Kingdom
-
RemeGen Co., Ltd.CompletedA Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's SyndromePrimary Sjögren's SyndromeChina
-
Millennium Pharmaceuticals, Inc.Approved for marketing
-
PfizerCompleted